Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Well-known assays for detection of circulating immune complexes (CIC) (C1 q binding assay, C1q deviation test, solid-phase C1 q binding assay, solid-phase conglutinin binding assay, and the platelet aggregation test) were used in 30 patients with different kinds of rapidly progressive glomerulonephritis. In 89% of the patients evidence of CIC was found in at least one of the assays. 81% of the patients were positive in the C1q binding assay and/or the conglutinin binding assay with addition of complement. CIC were more often detected by several assays, and with higher values in patients with systemic disease than in patients with renal involvement alone. CIC were found in 2 patients with Goodpasture's syndrome. 15 patients were reexamined after treatment with plasma exchange, when the disease was clinically inactive. The patients were still on immunosuppressive treatment. In most of these, CIC were detectable, but with lower values than at the start of treatment. Before treatment, high levels of C1r-C1s-C1 inactivator complexes suggested increased C1 activation in 93% of the patients. C-reactive protein was raised, and the concentrations of C1 q, C1s, C4, C3 and factor B were normal or high in most of the patients. Pronounced hypocomplementemia was found only in 2 patients with systemic lupus erythematosus (SLE). After treatment, the levels of C-reactive protein, C1 q, C1s, C3 and factor B had decreased in the non-SLE patients, while the average levels of C4 and C1r-C1s-C1 inactivator complexes were essentially unchanged.
 ...
PMID:Circulating immune complexes and C1 activation in patients with rapidly progressive glomerulonephritis, before and after treatment with immunosuppression and plasma exchange. 687 3

The structure, synthesis and possible functions of C-reactive protein (CRP) are discussed. CRP is a highly sensitive but non-specific indicator of tissue damage, but its diagnostic value in inflammatory rheumatic diseases is very limited. In SLE, a high level may suggest additional bacterial infection. While semiquantitative methods are of little help, the quantitative measurement of CRP can be used as both a clinical and a therapeutic parameter in patients in whom ESR does not parallel the inflammatory activity of the disease. Apart from these exceptions, CRP does not appear to offer major advantages over ESR in the day-to-day management of patients with inflammatory rheumatic diseases.
 ...
PMID:[C-reactive protein: should it be determined in inflammatory rheumatic diseases?]. 697 96

The significance of C-reactive protein (CRP) elevation in patients with systemic lupus erythematosus (SLE) in the pretreatment stage was assessed with reference to other laboratory data obtained simultaneously. Sixteen of 31 cases were CRP-positive, and the CR-positive group contained significantly more cases with urinary cellular casts and with a high anti-DNA antibody titer, compared with the CRP-negative group. We suggest that CRP in patients with SLE, as measured at the time of the first consultation, reflects the severity of the disease. This includes those cases complicated by nephropathy.
 ...
PMID:Significance of C-reactive protein elevation in the pretreatment stage of systemic lupus erythematosus. 697 90

The urinary excretion of sialic-acid-containing oligosaccharides, total sialic acid, serum amyloid A protein (SAA), and C-reactive protein (CRP) has been studied in 48 patients with rheumatoid arthritis (RA) and in 17 patients with systemic lupus erythematosus (SLE). Linear regression analysis revealed a close positive correlation between serum SAA and CRP levels in both RA (r = 0.71, p less than 0.001) and SLE (r = 0.86, p less than 0.001). The urinary excretion of sialyl lactose showed a positive correlation with the serum levels of SAA and CRP in RA (r = 0.45 and r = 0.45, respectively, p less than 0.01) but not in SLE (r = 0.05 and r = 0.10 respectively). Changes in serum total sialic acid levels paralleled those in CRP and SAA in RA as well as in SLE. Patients with very active RA had higher urinary sialyl oligosaccharide excretion (p less than 0.001), higher CRP levels (p less than 0.01), and higher SAA levels ( p less than 0.05) than those with moderately active disease.
 ...
PMID:Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. 709 39

The acute-phase plasma protein response to disease activity in murine models of autoimmune lupus-like disease was investigated by measurement of the concentration of serum amyloid P component (SAP) in NZB X W and MRL/l mice. The levels of SAP, which is a major acute-phase protein in mice, did not rise at all in response to progression of disease in NZB X W mice between the ages of 1 and 9 mo. This resembles the behavior of acute-phase proteins such as C-reactive protein and serum amyloid A protein in human systemic lupus erythematosus, and just as in human lupus, where the occurrence of intercurrent microbial infection can stimulate an acute-phase response, so injection of bacterial lipopolysaccharide or casein into the NZB X W mice stimulated "normal" acute-phase SAP production. In marked contrast, MRL/l mice developed greatly increased levels of SAP, which correlated closely with progression of their pathology as they aged. The disease profile of the MRL/l strain includes rheumatoid factors and spontaneous polyarthritis and their SAP response resembles the behavior of acute phase proteins in human rheumatoid arthritis. Different patterns of acute-phase response in different autoimmune disorders may thus be a reflection of the genetic predisposition to particular diseases and/or contribute to their pathogenesis. The existence of animal counterparts for the various clinical patterns of human acute-phase protein production will assist in experimental investigation of the underlying mechanisms and of the biological role of the acute-phase response.
 ...
PMID:The acute-phase response in (NZB X NZW)F1 and MRL/l MICE. 715 12

Fifty of 197 systemic lupus erythematosus (SLE) sera had 2 + positive C-reactive protein (CRP) determinations by precipitation in capillary tubes. All but 3 of these 50 sera had been taken at the time of infection whereas 80 of the 115 sera taken at the time of SLE activity without infection were negative for CRP. Thirty-two of the 35 CRP positive sera from patients with active lupus were obtained during intercurrent infection. CRP determinations in capillary tubes are clinically useful in distinguishing disease reactivation from intercurrent infection in SLE. These findings confirm a study using the same method for CRP determination. Discrepancy with another study may be due to the use of a different method.
 ...
PMID:C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE. 723 Jan 60

One hundred and ninety sera from 27 patients with systemic lupus erythematosus (SLE) were tested by radial immunodiffusion for C-reactive protein (CRP). One hundred and fourteen (60%) of these samples from 22 patients had detectable CRP. There was a statistically significant association between clinical activity and serum concentration of CRP in the patients who consistently recorded elevated levels. CRP was not found to distinguish between disease activity and coincident infection in 2 patients whose SLE was complicated by tuberculosis.
 ...
PMID:C-reactive protein in sera from patients with systemic lupus erythematosus. 729 61

The concentration of C-reactive protein (CRP) in the sera of patients with systemic lupus erythematosus (SLE) was higher when the disease was active than when it was inactive, but was only markedly raised in patients suffering from identifiable microbial infection. CRP levels greater than 60 mg/l suggest the presence of intercurrent infection and may therefore be a valuable aid to the differential diagnosis of pyrexia in SLE.
 ...
PMID:Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. 737 59

Tumor necrosis factor alpha (TNF alpha) and interleukin-6 (IL-6) play a main role in inducing acute phase protein production by hepatocytes. This study describes the serum levels of TNF alpha and IL-6 in relation to serum levels of C-reactive protein (CRP) and alpha 1-acid glycoprotein (alpha 1AG) in three systemic lupus erythematosus (SLE) patients. Disease courses of these patients were divided in a total of 19 clinical periods, according to the clinical symptoms and interleukin profiles. Significantly elevated TNF alpha levels were found in all but three of the defined periods, without being associated with disease activity. In only four of the defined periods elevated TNF alpha were observed combined with elevated IL-6 and CRP levels. Two of these periods coincided with minor symptoms of SLE, one with an exacerbation and the other one with a systemic infection while SLE activity was low. All other periods showed varying combinations of elevated TNF alpha and/or IL-6 levels being followed or not by elevated CRP levels. Significantly raised alpha 1AG levels were measured in all clinical periods. In most of the observed periods a dissociation was found between TNF alpha and IL-6 and also between the different cytokine (TNF alpha and IL-6) levels and acute phase protein (CRP and alpha 1AG) levels. These data could not be explained by differences in disease course or influences of medication. We conclude that more factors other than TNF alpha and IL-6 must play a role in the regulatory pathway of the acute phase response in SLE.(ABSTRACT TRUNCATED AT 250 WORDS)
Lupus 1993 Dec
PMID:Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. 751 Oct 20

To investigate the role of the complex IgA-alpha-1-antitrypsin (IgA-AT) in systemic lupus erythematosus (SLE) and in mixed connective tissue disease (MCTD), and its possible relations to either activity of the disease or a treatment, we examined a concentration of IgA-AT complex in 65 SLE and 9 MCTD sera. Complex IgA-AT was evaluated using a double antibody enzyme-linked immunoassay (ELISA). Twenty nine patients with SLE (44.6%) and three patients with MCTD (33.3%) had increased serum IgA-AT levels. The mean values of IgA-AT complex in patients with SLE and MCTD were higher than in healthy controls. Among the SLE group, patients with current neurological manifestation were characterized by an increase in IgA-AT serum concentration (2.45 +/- 2.07 U vs. 0.78 +/- 0.70 U, P < 0.001). No relation was found between this complex and ESR level, C-reactive protein (CRP) concentration, or hemoglobin level. Ten SLE patients were treated with CTX intravenously. In this group of patients, IgA-AT complex level was found to be increased compared with patients without such a treatment (1.82 +/- 1.30 U vs. 0.80 +/- 0.67 U, P < 0.05). The present study provides two new observations. Firstly, IgA-AT complex is increased in SLE and MCTD compared with healthy controls, and secondly, patients with CNS involvement displayed a striking increased IgA-AT level.
Lupus 1995 Jun
PMID:IgA-alpha-1-antitrypsin complex in systemic lupus erythematosus: preliminary report. 765 94


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>